OPPORTUNITY IN BIOTECH WITHIN BUYOUT POTENTIAL BEATING GOLD STANDARD IN LUNG CANCER TREATMENT
By Nigam Arora & Dr. Natasha Arora Better Than Gold Standard In a Phase 3 study, Summit Therapeutics Inc’s (SMMT) drug showed a statistically significant 5.3 months of improvement in progression free survival versus Keytruda in treatment of PD-L1- positive advanced non-small cell lung cancer. Keytruda from MRK is the gold standard.
September 25, 2024